CagriSema’s 25% average weight-loss estimate in women assumes continued treatment. Read the menopause findings and key limits of the analysis.
On October 20, 2026, Reuters reported that Novo Nordisk had released new analyses of CagriSema in women with overweight or obesity. The findings came from REDEFINE 1, a late-stage clinical trial. They examined weight change among women overall and across different stages of menopause.
The announcement gives women’s treatment response a more specific place in the discussion about obesity medicines. Rather than reporting only an overall trial average, the company looked more closely at participants across the reproductive lifespan.
For readers navigating weight management around midlife, that is a relevant research question. The important task is to separate the results from the expectations a headline can create. A reported average becomes useful only when its study population and underlying assumptions are clear.
CagriSema combines semaglutide with cagrilintide. According to CNBC, cagrilintide targets the amylin pathway. The report described CagriSema as an experimental injection, not an approved obesity treatment.
A biological pathway is a route through which signals act in the body. Saying that a medicine targets a pathway identifies part of the biological system it is designed to act on. In this case, the development strategy brings two drug components together in one combination.
The findings therefore concern CagriSema as a combination. They should not be read as results for either ingredient used by itself.
CNBC placed the announcement within a broader effort to develop amylin-based treatments alongside existing GLP-1 medicines. The scientific interest is in combining biological approaches rather than relying on a single component. WeightRestart’s coverage of medicines with multiple targets and oral options provides related context for that research direction.
For a reader, the distinction is straightforward: how a medicine is designed and what a trial demonstrates are separate questions. A combination strategy explains the research approach. The trial results provide the evidence used to judge its effects.
Reuters led its coverage with the finding that women lost 25% of their weight on average. CNBC also highlighted that result. Both outlets were reporting a company analysis, so the headline needs to be read with the statistical question behind it.
The treatment assumption matters. The women’s weight-loss estimates assumed that participants continued treatment without interruptions. That makes the 25% figure an estimate under continued treatment, rather than an ordinary-care result covering every possible pattern of treatment use. The menopause-stage estimates used that same assumption.
This is more than a technical footnote. It defines the circumstances attached to the result. When reading medication news, the useful question is not only “How much weight changed?” but also “Under what treatment conditions was that change estimated?”
The analyses were post hoc. Researchers examined the trial data afterward rather than conducting a trial whose primary question had been women’s or menopause-stage response. CNBC reported that further work is needed to confirm the hypotheses generated by these analyses. The appropriate interpretation is exploratory evidence that helps shape the next research questions.
A group average is not a personal forecast. These findings do not establish how much a particular person would lose or whether that person would tolerate or benefit from treatment. The numerical differences between menopause groups also do not prove that menopausal status caused a different response. They should not become targets assigned to women according to reproductive stage.
The full-trial figures add another important distinction. CNBC reported initial REDEFINE 1 results of 22.7% average weight loss with CagriSema versus 2.3% with placebo at week 68. Women made up about 67% of the roughly 3,400 participants.
Comparing that overall average with the women-only estimate does not establish that women respond better than men. The overall trial already included many of the women being discussed. Nor does the new analysis establish that CagriSema is more effective than another medicine, since comparisons across trials require attention to their populations and methods.
CNBC also described investor disappointment with earlier results and Novo’s view that the medicine could attract demand. Those are market assessments. Commercial expectations are not clinical evidence of superiority or a measure of whether a treatment would suit an individual.
For personal decisions, the useful next step is a discussion with a qualified clinician about suitability and expected benefits. Potential risks and follow-up belong in that conversation too. WeightRestart’s discussion of how medication and lifestyle support fit into care offers a broader framework without turning this investigational result into a treatment recommendation.
Reuters reported that the main women’s analysis included 2,309 participants with overweight or obesity who received CagriSema or placebo. CNBC reported average weight loss at week 68 of:
These are the headline findings from the women-focused analysis. They belong alongside the treatment assumption described above, rather than standing alone as an expected outcome.
A separate analysis assessed 1,902 women by menopausal status. According to Reuters and CNBC, the reported average weight-loss estimates at week 68 were:
Placebo results were approximately 2% across those groups.
Presenting the stages separately makes the research question more visible. It allows discussion of women’s reproductive lifespan without reducing the story to a single female average. The figures are best treated as a set of descriptive observations, not a ranking of which women should expect the most benefit.
Novo executive Michelle Skinner Moore said the company considers it important to study investigational treatments across women’s reproductive lifespan. CNBC reported that she cited weight gain during the transition through menopause as part of that rationale. Her statement explains the company’s interest in the question rather than providing independent confirmation of the findings.
The analyses also included an outcome beyond scale weight. CNBC reported reductions in waist circumference, which Novo used as an indicator of reduced abdominal fat. Its coverage did not provide a numerical estimate for that change.
Weight loss and body composition should remain separate. The reporting does not establish how much muscle participants retained or provide a complete account of changes in body tissues. A waist measurement adds information, but it does not answer every question about what changed as weight declined.
That distinction matters for how readers assess progress. It is reasonable to ask which outcomes were measured rather than assuming a weight-loss percentage describes every aspect of health. For related reading, WeightRestart examines the evidence around muscle preservation during weight loss.
The useful takeaway is therefore more specific than “a drug produced a large number.” Researchers reported substantial average weight change in women and supplied a breakdown across menopause stages. Those observations identify questions worth testing more directly.
The next important development would be research designed in advance to test the questions raised here. For menopause-related response, that means assessing whether the observed group differences persist and whether reproductive stage helps explain them. A study built around those questions would provide a firmer basis for interpreting the pattern.
Future reporting should also make treatment interruptions easy to understand. Readers need to know how results change when analyses account for different patterns of continued use. Clear safety and tolerability findings would help put weight-loss outcomes into a more useful clinical context.
More detailed reporting on waist measurements and body composition would also add value. Those outcomes would address different questions from the percentage change on the scale. They should be reported as findings in their own right rather than inferred from weight loss.
What to watch next is whether confirmatory research turns these observations into reliable guidance for care. Before CagriSema becomes a standard option, the meaningful signals are confirmed regulatory decisions and evidence that clarifies benefits and risks. The strongest next headline would help explain who benefits under which conditions, not simply report a larger percentage.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
